Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban

Table 5

Relative risk reductions (RRRs) of safety outcome event rates versus VKA control groups.

	RE-LY [21]		ROCKET AF [14]	ARISTOTLE [15]
	Dabigatran 110 mg	Dabigatran 150 mg	Rivaroxaban	Apixaban
Major bleed* RRR, %	↓ 20*	↓ 7	↑ 4	↓ 31*
Intracranial bleed** RRR, %	↓ 70*	↓ 59*	↓ 33*	↓ 58*
Fatal bleed RRR, %	—	—	↓ 50*	↓ 39^**#
Potentially lethal bleed RRR, %	↓ 33*	↓ 20*	—	—
Gastrointestinal bleed RRR, %	↑ 8	↑ 48*	↑ 46^*#	↓ 11
Major and nonmajor clinically relevant bleeds RRR, %^†	↓ 22*	↓ 9*	↑ 3	↓ 32*

RRR: relative risk reduction.
* P < 0.05.
**In modified intention-to-treat analysis, statistical significance was not reported.
^#Comparison was made using reported raw event frequencies, as annualised event rates were not available.